Clinical Trial Update: An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 trial evaluating Vebeglogene Autotemcel for transfusion-dependent beta-thalassemia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• Vebeglogene Autotemcel

Snippet

Sponsor: Lantu Biopharma | Conditions: Beta-Thalassemia | Phase 1, Phase 2 | Status: RECRUITING